Sumitomo Pharma Co., Ltd.: Neoplasms trials

The registry lists 12 Neoplasms studies with Sumitomo Pharma Co., Ltd. as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 1 10Phase 2 2Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung CancerTerminatedNCT02826161Phase 3Results posted
• Clinical Study of WT2725 in Patients With Advanced MalignanciesCompletedNCT01621542Phase 1Results posted
• A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced MalignanciesCompletedNCT01325441Phase 1/2Results posted
• Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored ProtocolsCompletedNCT04299880Phase 1
• Study of TP-3654 in Patients With Advanced Solid TumorsCompletedNCT03715504Phase 1
• First-in-human Study of Oral TP-0184 in Patients With Advanced Solid TumorsCompletedNCT03429218Phase 1
• A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced CancersCompletedNCT02467361Phase 1
• A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid TumorsCompletedNCT02432326Phase 1
• A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic MalignanciesCompletedNCT02352558Phase 1
• A Study of BBI503 in Adult Patients With Advanced Urologic MalignanciesWithdrawnNCT02232646Phase 2
• A Study of BBI503 in Adult Patients With Advanced Solid TumorsCompletedNCT01781455Phase 1
• A Study of BBI608 in Adult Patients With Advanced MalignanciesCompletedNCT01775423Phase 1